-0.000208460280298893 0.000897982745903049 0.00147525736826907 0.00320708123536769 0.00259773580064784 -0.0091632725056925 -0.00548410891247869 -0.00150732818062272
Sign Up Today X
Thanks for submitting the form.
Stockreport

Here Are the Obesity Drug Hopefuls Vying to Unseat Ozempic, Zepbound [BNN Bloomberg (Canada)]

Amgen Inc. (AMGN)  More Company Research Source: BNN Bloomberg
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
After Amgen Inc.'s chief executive officer, Robert Bradway, said he was “very encouraged” by early results of an experimental obesity shot, the stock on Friday leapt 16%, its biggest gain since 2009. That's despite no new data being released on the drug — which is in mid-stage trials — and before the approval process has even begun. The CEO's upbeat remarks not only lifted Amgen shares, but also sent Novo Nordisk A/S, the Danish maker of hit drugs Wegovy and Ozempic, tumbling by more than 5%. Eli Lilly & Co., which makes weight-loss shot Zepbound, fell almost 3% in early trading Friday. The potential size of the obesity drug market helps explain the excitement: Analysts at Goldman Sachs forecast it could hit $100 billion by 2030. Optimism over soaring sales has driven Novo Nordisk's market capitalization above $500 billion this year, reinforcing its position as Europe's most valuable listed company. Lilly's shares are up more than 75% in the past 12 months. Novo and Lilly are l [Read more]
IMPACT SNAPSHOT EVENT TIME: AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
AMGN alerts
from News Quantified
AMGN
NEWS
AMGN
Earnings
AMGN
Analyst Actions
AMGN
SEC Filings
Stockreport

Here Are the Obesity Drug Hopefuls Vying to Unseat Ozempic, Zepbound [BNN Bloomberg (Canada)]

Amgen Inc.  (AMGN) 
More Company Research Source: BNN Bloomberg
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
After Amgen Inc.'s chief executive officer, Robert Bradway, said he was “very encouraged” by early results of an experimental obesity shot, the stock on Friday leapt 16%, its biggest gain since 2009. That's despite no new data being released on the drug — which is in mid-stage trials — and before the approval process has even begun. The CEO's upbeat remarks not only lifted Amgen shares, but also sent Novo Nordisk A/S, the Danish maker of hit drugs Wegovy and Ozempic, tumbling by more than 5%. Eli Lilly & Co., which makes weight-loss shot Zepbound, fell almost 3% in early trading Friday. The potential size of the obesity drug market helps explain the excitement: Analysts at Goldman Sachs forecast it could hit $100 billion by 2030. Optimism over soaring sales has driven Novo Nordisk's market capitalization above $500 billion this year, reinforcing its position as Europe's most valuable listed company. Lilly's shares are up more than 75% in the past 12 months. Novo and Lilly are l [Read more]
IMPACT SNAPSHOT
EVENT TIME:
AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS